{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-023789","form_type":"8-K","ticker":"RFL","cik":"0001713863","company_name":"Rafael Holdings, Inc.","filed_at":"2025-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.560816+00:00","generated_at":"2026-05-24T18:40:13.267061+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rafael Holdings Q2 net loss $4.6M vs prior year net income; merger with Cyclo pending","bullets":["Net loss of $4.6M ($0.19/sh) for Q2 ended Jan 31, 2025 vs net income of $6.0M ($0.25/sh) a year ago.","Cash and equivalents at $48.3M as of January 31, 2025.","Merger with Cyclo Therapeutics (CYTH) expected to close in Q3 fiscal 2025 pending shareholder approvals.","Topline data from interim analysis (48 weeks) of Phase 3 Trappsol Cyclo for NPC1 expected mid-2025.","R&D expenses rose to $0.9M from $0.6M due to consolidation of Cornerstone and Day Three."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-023789","json":"https://secwatch.observer/filing/0001213900-25-023789.json","markdown":"https://secwatch.observer/filing/0001213900-25-023789.md","text":"https://secwatch.observer/filing/0001213900-25-023789.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1713863/000121390025023789/0001213900-25-023789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1713863/000121390025023789/ea0234181-8k_rafael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T18:40:13.267061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}